Immune-based strategies for mood disorders

facts and challenges

Gabriela D. Colpo, Marion Leboyer, Robert Dantzer, Mahdukar H. Trivedi, Antonio L. Teixeira

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.

Original languageEnglish (US)
Pages (from-to)139-152
Number of pages14
JournalExpert Review of Neurotherapeutics
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Mood Disorders
Major Depressive Disorder
Bipolar Disorder
Biomarkers
Inflammation
Probiotics
Acetylcysteine
Antidepressive Agents
Immune System
Anti-Inflammatory Agents
Stem Cells
Animal Models
Clinical Trials
Exercise
Cytokines
Acids
Therapeutics
Pharmaceutical Preparations

Keywords

  • anti-inflammatory drugs
  • bipolar disorder
  • cytokines
  • immunomodulation
  • inflammation
  • major depressive disorder
  • Mood disorders
  • neuroinflammation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Immune-based strategies for mood disorders : facts and challenges. / Colpo, Gabriela D.; Leboyer, Marion; Dantzer, Robert; Trivedi, Mahdukar H.; Teixeira, Antonio L.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 2, 01.02.2018, p. 139-152.

Research output: Contribution to journalReview article

Colpo, Gabriela D. ; Leboyer, Marion ; Dantzer, Robert ; Trivedi, Mahdukar H. ; Teixeira, Antonio L. / Immune-based strategies for mood disorders : facts and challenges. In: Expert Review of Neurotherapeutics. 2018 ; Vol. 18, No. 2. pp. 139-152.
@article{e82cc51101fe49e9b35f1fb0e5107394,
title = "Immune-based strategies for mood disorders: facts and challenges",
abstract = "Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.",
keywords = "anti-inflammatory drugs, bipolar disorder, cytokines, immunomodulation, inflammation, major depressive disorder, Mood disorders, neuroinflammation",
author = "Colpo, {Gabriela D.} and Marion Leboyer and Robert Dantzer and Trivedi, {Mahdukar H.} and Teixeira, {Antonio L.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/14737175.2018.1407242",
language = "English (US)",
volume = "18",
pages = "139--152",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Immune-based strategies for mood disorders

T2 - facts and challenges

AU - Colpo, Gabriela D.

AU - Leboyer, Marion

AU - Dantzer, Robert

AU - Trivedi, Mahdukar H.

AU - Teixeira, Antonio L.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.

AB - Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.

KW - anti-inflammatory drugs

KW - bipolar disorder

KW - cytokines

KW - immunomodulation

KW - inflammation

KW - major depressive disorder

KW - Mood disorders

KW - neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=85041306875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041306875&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1407242

DO - 10.1080/14737175.2018.1407242

M3 - Review article

VL - 18

SP - 139

EP - 152

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 2

ER -